Upgrade to SI Premium - Free Trial

Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers

December 14, 2021 9:02 AM

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma presented positive data on the effectiveness of LP-284 in hematologic cancers at the 63rd American Society of Hematology (ASH) Annual Meeting, which was held in-person and virtually from December 11 – 14, 2021. This poster presentation can be viewed on Lantern Pharma's website at: https://www.lanternpharma.com/about/publications.LP-284 is a fully synthetic molecule belonging to the new generation of acylfulvenes, a family of naturally derived anti-cancer drug candidates. LP-284 is the stereoisomer (enantiomer) of LP-184 and has the potential for development as monotherapy and also as a synergistic agent in combination with other drugs. LP-284 is currently being evaluated for activity in a wide spectrum of hematological cancers. Earlier this year, Lantern filed multi-national patent applications directed to both the composition and manufacture of LP-284.

LP-284 demonstrated nanomolar potency in a variety of hematologic cell lines

The study demonstrated LP-284's broad in vitro anti-tumor activity in lymphoma, multiple myeloma, and leukemia cells. Notably, the enantiomer pair, LP-184 and LP-284, exhibit distinct patterns of anti-tumor activities. As a result, the novel enantiomer LP-284 may provide a targeted therapy option for hematologic cancers with compromised DNA repair, supporting further targeted development plans for LP-284.

"Approximately every 3 minutes, one person in the U.S. is diagnosed with leukemia, lymphoma or myeloma and approximately every 9 minutes someone in the U.S. dies from a blood cancer1," commented Panna Sharma, CEO and President of Lantern Pharma Inc. "There is an urgent need to develop new, targeted therapies; however, the current industry approach is time consuming and expensive. This latest data provides further validation of Lantern's RADR® platform, which leverages A.I. and machine learning with the aim of dramatically shortening the timeline and reducing costs associated with drug discovery and development. Specifically, these findings support our hypothesis that LP-284 has the potential to become a targeted therapy option for hematologic cancers with compromised DNA repair. We plan to apply the insights obtained from this work to advance the development of LP-284 in rare blood cancer indications. This data is very encouraging, and we look forward to advancing LP-284 towards the clinic, while leveraging our RADR® platform to develop new cutting-edge treatments for rare blood cancers and other indications."

Lantern's proprietary RADR® A.I. platform leverages over 10 billion data points, machine learning, genomics, and computational biology to accelerate the discovery of potential mechanisms of action, and biomarker signatures that correlate to drug response in rare blood cancers.


Corporate News FDA

Next Articles